

Metastatic Ovarian Cancer Drug Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/ME35FDD0FE96EN.html>

Date: March 2022

Pages: 78

Price: US\$ 3,250.00 (Single User License)

ID: ME35FDD0FE96EN

Abstracts

This report contains market size and forecasts of Metastatic Ovarian Cancer Drug in global, including the following market information:

Global Metastatic Ovarian Cancer Drug Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Metastatic Ovarian Cancer Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)

Global top five Metastatic Ovarian Cancer Drug companies in 2021 (%)

The global Metastatic Ovarian Cancer Drug market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

E-7449 Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Metastatic Ovarian Cancer Drug include Adgero Biopharmaceuticals Inc, Cellceutix Corporation, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited and Northwest Biotherapeutics, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metastatic Ovarian Cancer Drug manufacturers, suppliers, distributors and industry experts on this industry,

involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Metastatic Ovarian Cancer Drug Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Metastatic Ovarian Cancer Drug Market Segment Percentages, by Type, 2021 (%)

E-7449

Crizotinib

CMB-305

G-305

LV-305

Others

Global Metastatic Ovarian Cancer Drug Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Metastatic Ovarian Cancer Drug Market Segment Percentages, by Application, 2021 (%)

Clinic

Hospital

Others

Global Metastatic Ovarian Cancer Drug Market, By Region and Country, 2017-2022,

2023-2028 (\$ Millions) & (K Pcs)

Global Metastatic Ovarian Cancer Drug Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Metastatic Ovarian Cancer Drug revenues in global market, 2017-2022
(Estimated), (\$ millions)

Key companies Metastatic Ovarian Cancer Drug revenues share in global market, 2021
(%)

Key companies Metastatic Ovarian Cancer Drug sales in global market, 2017-2022
(Estimated), (K Pcs)

Key companies Metastatic Ovarian Cancer Drug sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Adgero Biopharmaceuticals Inc

Cellceutix Corporation

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Immune Design Corp.

Millennium Pharmaceuticals Inc

MolMed S.p.A.

Natco Pharma Limited

Northwest Biotherapeutics, Inc.

Pfizer Inc.

Richter Gedeon Nyrt.

Sumitomo Dainippon Pharma Co., Ltd.

VG Life Sciences, Inc.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Metastatic Ovarian Cancer Drug Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Metastatic Ovarian Cancer Drug Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL METASTATIC OVARIAN CANCER DRUG OVERALL MARKET SIZE

- 2.1 Global Metastatic Ovarian Cancer Drug Market Size: 2021 VS 2028
- 2.2 Global Metastatic Ovarian Cancer Drug Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Metastatic Ovarian Cancer Drug Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Metastatic Ovarian Cancer Drug Players in Global Market
- 3.2 Top Global Metastatic Ovarian Cancer Drug Companies Ranked by Revenue
- 3.3 Global Metastatic Ovarian Cancer Drug Revenue by Companies
- 3.4 Global Metastatic Ovarian Cancer Drug Sales by Companies
- 3.5 Global Metastatic Ovarian Cancer Drug Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Metastatic Ovarian Cancer Drug Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Metastatic Ovarian Cancer Drug Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Metastatic Ovarian Cancer Drug Players in Global Market
 - 3.8.1 List of Global Tier 1 Metastatic Ovarian Cancer Drug Companies
 - 3.8.2 List of Global Tier 2 and Tier 3 Metastatic Ovarian Cancer Drug Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Metastatic Ovarian Cancer Drug Market Size Markets, 2021 & 2028

4.1.2 E-7449

4.1.3 Crizotinib

4.1.4 CMB-305

4.1.5 G-305

4.1.6 LV-305

4.1.7 Others

4.2 By Type - Global Metastatic Ovarian Cancer Drug Revenue & Forecasts

4.2.1 By Type - Global Metastatic Ovarian Cancer Drug Revenue, 2017-2022

4.2.2 By Type - Global Metastatic Ovarian Cancer Drug Revenue, 2023-2028

4.2.3 By Type - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

4.3 By Type - Global Metastatic Ovarian Cancer Drug Sales & Forecasts

4.3.1 By Type - Global Metastatic Ovarian Cancer Drug Sales, 2017-2022

4.3.2 By Type - Global Metastatic Ovarian Cancer Drug Sales, 2023-2028

4.3.3 By Type - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

4.4 By Type - Global Metastatic Ovarian Cancer Drug Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Metastatic Ovarian Cancer Drug Market Size, 2021 & 2028

5.1.2 Clinic

5.1.3 Hospital

5.1.4 Others

5.2 By Application - Global Metastatic Ovarian Cancer Drug Revenue & Forecasts

5.2.1 By Application - Global Metastatic Ovarian Cancer Drug Revenue, 2017-2022

5.2.2 By Application - Global Metastatic Ovarian Cancer Drug Revenue, 2023-2028

5.2.3 By Application - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

5.3 By Application - Global Metastatic Ovarian Cancer Drug Sales & Forecasts

5.3.1 By Application - Global Metastatic Ovarian Cancer Drug Sales, 2017-2022

5.3.2 By Application - Global Metastatic Ovarian Cancer Drug Sales, 2023-2028

5.3.3 By Application - Global Metastatic Ovarian Cancer Drug Sales Market Share,

2017-2028

5.4 By Application - Global Metastatic Ovarian Cancer Drug Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Metastatic Ovarian Cancer Drug Market Size, 2021 & 2028

6.2 By Region - Global Metastatic Ovarian Cancer Drug Revenue & Forecasts

6.2.1 By Region - Global Metastatic Ovarian Cancer Drug Revenue, 2017-2022

6.2.2 By Region - Global Metastatic Ovarian Cancer Drug Revenue, 2023-2028

6.2.3 By Region - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

6.3 By Region - Global Metastatic Ovarian Cancer Drug Sales & Forecasts

6.3.1 By Region - Global Metastatic Ovarian Cancer Drug Sales, 2017-2022

6.3.2 By Region - Global Metastatic Ovarian Cancer Drug Sales, 2023-2028

6.3.3 By Region - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

6.4 North America

6.4.1 By Country - North America Metastatic Ovarian Cancer Drug Revenue, 2017-2028

6.4.2 By Country - North America Metastatic Ovarian Cancer Drug Sales, 2017-2028

6.4.3 US Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.4.4 Canada Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.4.5 Mexico Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.5 Europe

6.5.1 By Country - Europe Metastatic Ovarian Cancer Drug Revenue, 2017-2028

6.5.2 By Country - Europe Metastatic Ovarian Cancer Drug Sales, 2017-2028

6.5.3 Germany Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.5.4 France Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.5.5 U.K. Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.5.6 Italy Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.5.7 Russia Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.5.8 Nordic Countries Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.5.9 Benelux Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.6 Asia

6.6.1 By Region - Asia Metastatic Ovarian Cancer Drug Revenue, 2017-2028

6.6.2 By Region - Asia Metastatic Ovarian Cancer Drug Sales, 2017-2028

6.6.3 China Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.6.4 Japan Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.6.5 South Korea Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.6.6 Southeast Asia Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.6.7 India Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Metastatic Ovarian Cancer Drug Revenue, 2017-2028

6.7.2 By Country - South America Metastatic Ovarian Cancer Drug Sales, 2017-2028

6.7.3 Brazil Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.7.4 Argentina Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales, 2017-2028

6.8.3 Turkey Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.8.4 Israel Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.8.5 Saudi Arabia Metastatic Ovarian Cancer Drug Market Size, 2017-2028

6.8.6 UAE Metastatic Ovarian Cancer Drug Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Adgero Biopharmaceuticals Inc

7.1.1 Adgero Biopharmaceuticals Inc Corporate Summary

7.1.2 Adgero Biopharmaceuticals Inc Business Overview

7.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Major Product Offerings

7.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)

7.1.5 Adgero Biopharmaceuticals Inc Key News

7.2 Cellceutix Corporation

7.2.1 Cellceutix Corporation Corporate Summary

7.2.2 Cellceutix Corporation Business Overview

7.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Major Product Offerings

7.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)

7.2.5 Cellceutix Corporation Key News

7.3 Eisai Co., Ltd.

7.3.1 Eisai Co., Ltd. Corporate Summary

7.3.2 Eisai Co., Ltd. Business Overview

- 7.3.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Major Product Offerings
- 7.3.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
- 7.3.5 Eisai Co., Ltd. Key News
- 7.4 F. Hoffmann-La Roche Ltd.
 - 7.4.1 F. Hoffmann-La Roche Ltd. Corporate Summary
 - 7.4.2 F. Hoffmann-La Roche Ltd. Business Overview
 - 7.4.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Major Product Offerings
 - 7.4.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
 - 7.4.5 F. Hoffmann-La Roche Ltd. Key News
- 7.5 Immune Design Corp.
 - 7.5.1 Immune Design Corp. Corporate Summary
 - 7.5.2 Immune Design Corp. Business Overview
 - 7.5.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Major Product Offerings
 - 7.5.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
 - 7.5.5 Immune Design Corp. Key News
- 7.6 Millennium Pharmaceuticals Inc
 - 7.6.1 Millennium Pharmaceuticals Inc Corporate Summary
 - 7.6.2 Millennium Pharmaceuticals Inc Business Overview
 - 7.6.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Major Product Offerings
 - 7.6.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
 - 7.6.5 Millennium Pharmaceuticals Inc Key News
- 7.7 MolMed S.p.A.
 - 7.7.1 MolMed S.p.A. Corporate Summary
 - 7.7.2 MolMed S.p.A. Business Overview
 - 7.7.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Major Product Offerings
 - 7.7.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
 - 7.7.5 MolMed S.p.A. Key News
- 7.8 Natco Pharma Limited
 - 7.8.1 Natco Pharma Limited Corporate Summary
 - 7.8.2 Natco Pharma Limited Business Overview
 - 7.8.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Major Product Offerings
 - 7.8.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales and Revenue in

Global (2017-2022)

7.8.5 Natco Pharma Limited Key News

7.9 Northwest Biotherapeutics, Inc.

7.9.1 Northwest Biotherapeutics, Inc. Corporate Summary

7.9.2 Northwest Biotherapeutics, Inc. Business Overview

7.9.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Major Product Offerings

7.9.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)

7.9.5 Northwest Biotherapeutics, Inc. Key News

7.10 Pfizer Inc.

7.10.1 Pfizer Inc. Corporate Summary

7.10.2 Pfizer Inc. Business Overview

7.10.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Major Product Offerings

7.10.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)

7.10.5 Pfizer Inc. Key News

7.11 Richter Gedeon Nyrt.

7.11.1 Richter Gedeon Nyrt. Corporate Summary

7.11.2 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Business Overview

7.11.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Major Product Offerings

7.11.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)

7.11.5 Richter Gedeon Nyrt. Key News

7.12 Sumitomo Dainippon Pharma Co., Ltd.

7.12.1 Sumitomo Dainippon Pharma Co., Ltd. Corporate Summary

7.12.2 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Business Overview

7.12.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Major Product Offerings

7.12.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)

7.12.5 Sumitomo Dainippon Pharma Co., Ltd. Key News

7.13 VG Life Sciences, Inc.

7.13.1 VG Life Sciences, Inc. Corporate Summary

7.13.2 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Business Overview

7.13.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Major Product Offerings

7.13.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)

7.13.5 VG Life Sciences, Inc. Key News

8 GLOBAL METASTATIC OVARIAN CANCER DRUG PRODUCTION CAPACITY, ANALYSIS

8.1 Global Metastatic Ovarian Cancer Drug Production Capacity, 2017-2028

8.2 Metastatic Ovarian Cancer Drug Production Capacity of Key Manufacturers in Global Market

8.3 Global Metastatic Ovarian Cancer Drug Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

10 METASTATIC OVARIAN CANCER DRUG SUPPLY CHAIN ANALYSIS

10.1 Metastatic Ovarian Cancer Drug Industry Value Chain

10.2 Metastatic Ovarian Cancer Drug Upstream Market

10.3 Metastatic Ovarian Cancer Drug Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Metastatic Ovarian Cancer Drug Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Metastatic Ovarian Cancer Drug in Global Market

Table 2. Top Metastatic Ovarian Cancer Drug Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Metastatic Ovarian Cancer Drug Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Metastatic Ovarian Cancer Drug Revenue Share by Companies, 2017-2022

Table 5. Global Metastatic Ovarian Cancer Drug Sales by Companies, (K Pcs), 2017-2022

Table 6. Global Metastatic Ovarian Cancer Drug Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Metastatic Ovarian Cancer Drug Price (2017-2022) & (USD/Pcs)

Table 8. Global Manufacturers Metastatic Ovarian Cancer Drug Product Type

Table 9. List of Global Tier 1 Metastatic Ovarian Cancer Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Metastatic Ovarian Cancer Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Metastatic Ovarian Cancer Drug Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Metastatic Ovarian Cancer Drug Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2017-2022

Table 15. By Type - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2023-2028

Table 16. By Application – Global Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Application - Global Metastatic Ovarian Cancer Drug Revenue (US\$, Mn), 2017-2022

Table 18. By Application - Global Metastatic Ovarian Cancer Drug Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2017-2022

Table 20. By Application - Global Metastatic Ovarian Cancer Drug Sales (K Pcs),

2023-2028

Table 21. By Region – Global Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Metastatic Ovarian Cancer Drug Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Metastatic Ovarian Cancer Drug Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2017-2022

Table 25. By Region - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2023-2028

Table 26. By Country - North America Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022

Table 29. By Country - North America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028

Table 30. By Country - Europe Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022

Table 33. By Country - Europe Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028

Table 34. By Region - Asia Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022

Table 37. By Region - Asia Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028

Table 38. By Country - South America Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022

Table 41. By Country - South America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028

Table 42. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022

Table 45. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028

Table 46. Adgero Biopharmaceuticals Inc Corporate Summary

Table 47. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Offerings

Table 48. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 49. Cellceutix Corporation Corporate Summary

Table 50. Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Offerings

Table 51. Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 52. Eisai Co., Ltd. Corporate Summary

Table 53. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Offerings

Table 54. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 55. F. Hoffmann-La Roche Ltd. Corporate Summary

Table 56. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Offerings

Table 57. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 58. Immune Design Corp. Corporate Summary

Table 59. Immune Design Corp. Metastatic Ovarian Cancer Drug Product Offerings

Table 60. Immune Design Corp. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 61. Millennium Pharmaceuticals Inc Corporate Summary

Table 62. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Offerings

Table 63. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 64. MolMed S.p.A. Corporate Summary

Table 65. MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Offerings

Table 66. MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 67. Natco Pharma Limited Corporate Summary

Table 68. Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Offerings

Table 69. Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 70. Northwest Biotherapeutics, Inc. Corporate Summary

Table 71. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Offerings

Table 72. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 73. Pfizer Inc. Corporate Summary

Table 74. Pfizer Inc. Metastatic Ovarian Cancer Drug Product Offerings

Table 75. Pfizer Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 76. Richter Gedeon Nyrt. Corporate Summary

Table 77. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Offerings

Table 78. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 79. Sumitomo Dainippon Pharma Co., Ltd. Corporate Summary

Table 80. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Offerings

Table 81. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 82. VG Life Sciences, Inc. Corporate Summary

Table 83. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Offerings

Table 84. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 85. Metastatic Ovarian Cancer Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)

Table 86. Global Metastatic Ovarian Cancer Drug Capacity Market Share of Key Manufacturers, 2020-2022

Table 87. Global Metastatic Ovarian Cancer Drug Production by Region, 2017-2022 (K Pcs)

Table 88. Global Metastatic Ovarian Cancer Drug Production by Region, 2023-2028 (K Pcs)

Table 89. Metastatic Ovarian Cancer Drug Market Opportunities & Trends in Global Market

Table 90. Metastatic Ovarian Cancer Drug Market Drivers in Global Market

Table 91. Metastatic Ovarian Cancer Drug Market Restraints in Global Market

Table 92. Metastatic Ovarian Cancer Drug Raw Materials

Table 93. Metastatic Ovarian Cancer Drug Raw Materials Suppliers in Global Market

Table 94. Typical Metastatic Ovarian Cancer Drug Downstream

Table 95. Metastatic Ovarian Cancer Drug Downstream Clients in Global Market

Table 96. Metastatic Ovarian Cancer Drug Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Metastatic Ovarian Cancer Drug Segment by Type

Figure 2. Metastatic Ovarian Cancer Drug Segment by Application

Figure 3. Global Metastatic Ovarian Cancer Drug Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Metastatic Ovarian Cancer Drug Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Metastatic Ovarian Cancer Drug Revenue, 2017-2028 (US\$, Mn)

Figure 7. Metastatic Ovarian Cancer Drug Sales in Global Market: 2017-2028 (K Pcs)

Figure 8. The Top 3 and 5 Players Market Share by Metastatic Ovarian Cancer Drug Revenue in 2021

Figure 9. By Type - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

Figure 10. By Type - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 11. By Type - Global Metastatic Ovarian Cancer Drug Price (USD/Pcs), 2017-2028

Figure 12. By Application - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

Figure 13. By Application - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 14. By Application - Global Metastatic Ovarian Cancer Drug Price (USD/Pcs), 2017-2028

Figure 15. By Region - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

Figure 16. By Region - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 17. By Country - North America Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 18. By Country - North America Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

Figure 19. US Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 20. Canada Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 21. Mexico Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 22. By Country - Europe Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Metastatic Ovarian Cancer Drug Sales Market Share,

2017-2028

Figure 24. Germany Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 25. France Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

Figure 33. China Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 37. India Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 39. By Country - South America Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

Figure 40. Brazil Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028

Figure 44. Turkey Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Metastatic Ovarian Cancer Drug Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Metastatic Ovarian Cancer Drug Production Capacity (K Pcs), 2017-2028

Figure 49. The Percentage of Production Metastatic Ovarian Cancer Drug by Region, 2021 VS 2028

Figure 50. Metastatic Ovarian Cancer Drug Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Metastatic Ovarian Cancer Drug Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/ME35FDD0FE96EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ME35FDD0FE96EN.html>